At a glance
- Originator Cancer Research Technology; University of Colorado at Denver; University of Salford
- Developer Allos Therapeutics
- Class Antineoplastics; Aziridines; Benzoquinones; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 06 Sep 2012 Allos Therapeutics has been acquired by Spectrum Pharmaceuticals
- 09 Mar 2009 Rh 1 is available for licensing outside the US (http://www.allos.com)
- 14 Nov 2007 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (IV)